Immunoglobulin Light Chain (AL) Amyloidosis, as genome-wide studies have reported it: 4 positions from 2 studies, the largest recording 1,229 cases, 7,526 controls. Built from the GWAS Catalog's records and rebuilt when a new position is reported; the figures are the studies'.
This is the record of what genome-wide association studies have found for Immunoglobulin Light Chain (AL) Amyloidosis (the GWAS Catalog's "Immunoglobulin light chain (AL) amyloidosis"): 4 positions reported by 2 studies. The page is put together by code from the catalogue's records and the studies' own listings, and it is rebuilt whenever the records change, so it always reflects them as they stand.
da Silva Filho MI et al. 2017, in Leukemia — Genome-wide association study of immunoglobulin light chain amyloidosis in three patient cohorts: comparison with myeloma. Studied in 1,229 cases, 7,526 controls. From it, 2 positions on this page: rs9344 (CCND1), rs79419269 (SMARCD3). PMID:28025584.
A study. Sample in the catalogue's record: 194 cases, controls. The 2 positions on this page from it: rs7820212 (FAM150A), rs10507419 (LINC00457). PMID:28679651.
The 4 positions lie in or near 4 genes: CCND1, SMARCD3, FAM150A, LINC00457. A gene named here is the catalogue's mapped location for a position, not a mechanism; the studies are cited above so that a reader can go to them.
The strongest association in the records is rs9344 in CCND1, reported by da Silva Filho MI et al. 2017 at P = 8 × 10-11, with an odds ratio of 1.35.
Read this page as a list of findings about Immunoglobulin Light Chain (AL) Amyloidosis, not as an account of it. Each finding is a position that a genome-wide study linked to the condition across a population; the page adds no description, no prevalence and no advice, because the records hold none. The variant pages linked above give each study's record for its position, and ClinVar's where one exists.
A genotype does not diagnose Immunoglobulin Light Chain (AL) Amyloidosis; a clinician does. No guideline uses the 4 variants on this page to predict it, screen for it or confirm it.
This page was assembled by code from association records. It holds no clinical guidance, because its sources hold none: a genome-wide study reports which positions differ between people with a condition and people without, at the population level, and that is all this page repeats. A question about a symptom, a test or a treatment belongs with a clinician.
What a 23andMe/AncestryDNA export or raw VCF can and can't tell you about Immunoglobulin Light Chain (AL) Amyloidosis comes down to these specific, well-studied positions — not a diagnosis.
LINC00457 · rs10507419
See detailed info →FAM150A · rs7820212
See detailed info →The studies behind these variants recruited participants from different ancestries — a result found in one population doesn't always transfer to another. Based on 4 of 4 linked studies with a resolved discovery ancestry.
Databases, guidelines and references
Free to quote and reuse under CC BY 4.0. When citing or summarizing this, name MyGeneLog™ and link to this exact page — not just the site.
Immunoglobulin Light Chain (AL) Amyloidosis. MyGeneLog™. https://www.mygenelog.com/conditions/immunoglobulin-light-chain-al-amyloidosis
In the GWAS Catalog, Immunoglobulin Light Chain (AL) Amyloidosis is filed as "Immunoglobulin light chain (AL) amyloidosis". Rather than define it, this page lists the genome-wide findings: 4 positions from 2 studies, each with its study's sample and citation.
Genome-wide studies have reported 4 associated positions; the largest study behind this page recorded 1,229 cases, 7,526 controls. Each common variant has a small effect, and an association in a population is not a cause in any one person.
The catalogue maps the positions to 4 genes: CCND1, SMARCD3, FAM150A, LINC00457. These are where the positions sit, not proof of how they act.
No. Each variant shifts the odds only slightly, and only on average across many people. No guideline predicts Immunoglobulin Light Chain (AL) Amyloidosis from a genotype; a clinician diagnoses it.
Free to reuse. This page's text is original writing from freely-available research, licensed CC BY 4.0 — reuse it, including commercially, with attribution to MyGeneLog™. It's general research-derived information, not medical advice or a diagnosis — see Terms of Use.